Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Br J Clin Pharmacol. 2023 Mar;89(3):1176-1186. doi: 10.1111/bcp.15569. Epub 2022 Nov 8.
Amodiaquine is a 4-aminoquinoline used extensively for the treatment and prevention of malaria. Orally administered amodiaquine is largely converted to the active metabolite desethylamodiaquine. Amodiaquine can cause bradycardia, hypotension, and electrocardiograph QT interval prolongation, but the relationship of these changes to drug concentrations is not well characterized.
We conducted a secondary analysis of a pharmacokinetic study of the cardiac safety of amodiaquine (10 mg base/kg/day over 3 days) in 54 Kenyan adults (≥18 years) with uncomplicated malaria. Nonlinear mixed effects modelling was used to assess amodiaquine and desethylamodiaquine concentration-effect relationships for vital sign (pulse rate, blood pressure) and electrocardiograph interval (QT, QRS, PR) outcomes. We also measured the spontaneous beating heart rate after cumulative dosing of amodiaquine and desethylamodiaquine in isolated mouse atrial preparations.
Amodiaquine and desethylamodiaquine caused concentration-dependent mean decreases in pulse rate (1.9 beats/min per 100 nmol/L; 95% confidence interval: 1.5-2.4), supine systolic blood pressure (1.7 mmHg per 100 nmol/L; 1.2-2.1), erect systolic blood pressure (1.5 mmHg per 100 nmol/L; 1.0-2.0) and erect diastolic blood pressure (1.4 mmHg per 100 nmol/L; 1.0-1.7). The mean QT interval prolongation was 1.4 ms per 100 nmol/L irrespective of correction factor after adjustment for residual heart rate dependency. There was no significant effect of drug concentration on postural change in blood pressure or PR and QRS intervals. In mouse atria, the spontaneous beating rate was significantly reduced by amodiaquine (n = 6) and desethylamodiaquine (n = 8) at 3 μmol/L (amodiaquine: 10 ± 2%; desethylamodiaquine: 12 ± 3%) and 10 μmol/L (amodiaquine: 50 ± 7%; desethylamodiaquine: 46 ± 6%) concentrations with no significant difference in potency between the 2 compounds.
Amodiaquine and desethylamodiaquine have concentration-dependent effects on heart rate, blood pressure, and ventricular repolarization.
阿莫地喹是一种广泛用于治疗和预防疟疾的 4-氨基喹啉。口服阿莫地喹主要转化为活性代谢物去乙基阿莫地喹。阿莫地喹可引起心动过缓、低血压和心电图 QT 间期延长,但这些变化与药物浓度的关系尚未很好地描述。
我们对 54 例肯尼亚成年人(≥18 岁)进行了阿莫地喹(3 天每天 10mg 碱基/kg)心脏安全性的药代动力学研究的二次分析。非线性混合效应模型用于评估生命体征(脉搏率、血压)和心电图间隔(QT、QRS、PR)结果的阿莫地喹和去乙基阿莫地喹浓度-效应关系。我们还在分离的小鼠心房制剂中测量了累积给予阿莫地喹和去乙基阿莫地喹后的自发心跳率。
阿莫地喹和去乙基阿莫地喹引起的平均脉搏率(每 100nmol/L 降低 1.9 次/分钟;95%置信区间:1.5-2.4)、仰卧位收缩压(每 100nmol/L 降低 1.7mmHg;1.2-2.1)、直立收缩压(每 100nmol/L 降低 1.5mmHg;1.0-2.0)和直立舒张压(每 100nmol/L 降低 1.4mmHg;1.0-1.7)呈浓度依赖性降低。在调整残余心率依赖性后,无论校正因素如何,QT 间期延长的平均值均为 1.4ms/100nmol/L。药物浓度对血压或 PR 和 QRS 间隔的体位变化无显著影响。在小鼠心房中,阿莫地喹(n=6)和去乙基阿莫地喹(n=8)在 3μmol/L(阿莫地喹:10±2%;去乙基阿莫地喹:12±3%)和 10μmol/L(阿莫地喹:50±7%;去乙基阿莫地喹:46±6%)浓度下显著降低了自发跳动率,两种化合物之间的效力无显著差异。
阿莫地喹和去乙基阿莫地喹对心率、血压和心室复极有浓度依赖性影响。